TABLE 3.

Key Findings from Literature Regarding Presence or Absence of Flare Phenomenon on PSMA-Targeted PET on Initiation of Androgen-Axis Targeted Therapeutic Agents

Study	Patients (n)	Therapy initiated	Key results
Hope (7)	1	ADT	Flare on 4-wk follow-up scan
Afshar-Oromieh (8)	10	ADT	Long-term ADT, decreased conspicuity of lesions
Aggarwal (10)	8	ADT in 4 patients, enzalutamide in 4 patients	Variably observed heterogeneous flare
Emmett (19)	15	ADT in 8 patients, enzalutamide or abiraterone in 7 patients	Mix of flare and true progression
Plouznikoff (11)	26	Enzalutamide or abiraterone	No evidence of flare

ADT = androgen deprivation therapy.